作为港股“基因编辑第一股”,百奥赛图二次冲刺科创板的上市之路并不顺利。近期,百奥赛图再次更新了招股书,2024年以来虽然扭亏为盈,经营性现金流转正,但关于研发投入、关联交易、实控人债务等争议还在持续发酵。01博士后创业港交所上市后再战科创板百奥赛图作为模式动物“三巨头”之一,致力于模式动物销售和临床医药研发,仅凭小白鼠生意就催生了百亿港元市值,也被市场称为“中国鼠王”。百奥赛图创始人沈月雷在求学...
Source Link作为港股“基因编辑第一股”,百奥赛图二次冲刺科创板的上市之路并不顺利。近期,百奥赛图再次更新了招股书,2024年以来虽然扭亏为盈,经营性现金流转正,但关于研发投入、关联交易、实控人债务等争议还在持续发酵。01博士后创业港交所上市后再战科创板百奥赛图作为模式动物“三巨头”之一,致力于模式动物销售和临床医药研发,仅凭小白鼠生意就催生了百亿港元市值,也被市场称为“中国鼠王”。百奥赛图创始人沈月雷在求学...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.